2. Search Result
Search Result
Pathways Recommended: MAPK/ERK Pathway
Results for "

mevalonate pathway

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

2

Biochemical Assay Reagents

16

Natural
Products

6

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N9474
    Mevalonic acid 5-pyrophosphate tetralithium

    5-Diphosphomevalonic acid tetralithium; Mevalonic acid 5-diphosphate tetralithium

    		 Endogenous Metabolite Others
    Mevalonic acid 5-pyrophosphate (5-Diphosphomevalonic acid) tetralithium is an endogenous metabolite of the mevalonate pathway .
    Mevalonic acid 5-pyrophosphate tetralithium
  • HY-113071A
    Mevalonic acid lithium salt
    Maximum Cited Publications
    9 Publications Verification

    MVA lithium salt

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .
    Mevalonic acid lithium salt
  • HY-W011474
    Geranylgeraniol

    		NF-κB Inflammation/Immunology
    Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model .
    Geranylgeraniol
  • HY-W011474R
    Geranylgeraniol (Standard)

    		Reference Standards NF-κB Inflammation/Immunology
    Geranylgeraniol (Standard) is the analytical standard of Geranylgeraniol. This product is intended for research and analytical applications. Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model [4].
    Geranylgeraniol (Standard)
  • HY-W011209
    N6-Isopentenyladenosine
    1 Publications Verification

    Riboprine

    		 Autophagy Endogenous Metabolite Cancer
    N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity .
    N6-Isopentenyladenosine
  • HY-113071
    Mevalonic acid

    MVA

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevalonic acid (MVA) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
    Mevalonic acid
  • HY-113071C
    (S)-Mevalonic acid

    (S)-MVA

    		 Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease
    (S)-Mevalonic acid is the isomer of Mevalonic acid (HY-113071). Mevalonic acid ((S)-DCIT) is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid can be used in studies of myopathy and heart failure .
    (S)-Mevalonic acid
  • HY-113071AR
    Mevalonic acid lithium salt (Standard)

    MVA lithium salt (Standard)

    		 Reference Standards Endogenous Metabolite Cardiovascular Disease Neurological Disease Metabolic Disease
    Mevalonic acid lithium salt (Standard) is the analytical standard of Mevalonic acid lithium salt. This product is intended for research and analytical applications. Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. Mevalonic acid lithium salt is effective in inhibiting Simvastatin (HY-17502)-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure .
    Mevalonic acid lithium salt (Standard)
  • HY-W011209R
    N6-Isopentenyladenosine (Standard)

    		Autophagy Endogenous Metabolite Cancer
    N6-Isopentenyladenosine (Riboprine), an RNA modification found in cytokinins, which regulate plant growth/differentiation, and a subset of tRNAs, where it improves the efficiency and accuracy of translation. N6-Isopentenyladenosine, an end product of the mevalonate pathway, is an autophagy inhibitor with an interesting anti-melanoma activity .
    N6-Isopentenyladenosine (Standard)
  • HY-113037
    (E/Z)-Farnesyl pyrophosphate

    (E/Z)-Farnesyl diphosphate

    		 TRP Channel Endogenous Metabolite Neurological Disease
    (E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .
    (E/Z)-Farnesyl pyrophosphate
  • HY-W011474S
    Geranylgeraniol-d5

    		Isotope-Labeled Compounds NF-κB Inflammation/Immunology
    Geranylgeraniol-d5 is the deuterium labeled Geranylgeraniol (HY-W011474). Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model .
    Geranylgeraniol-d5
  • HY-N7392
    Acetoacetyl-CoA

    3-Oxobutanoyl-coenzyme A

    		 Endogenous Metabolite Metabolic Disease
    Acetoacetyl CoA is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA from two acetyl-CoA molecules. Acetoacetyl CoA is essential for cholesterol biosynthesis. Acetoacetyl-CoA is also a intermediate in the biological breakdown and synthesis of fatty acids .
    Acetoacetyl-CoA
  • HY-N7392A
    Acetoacetyl-CoA sodium hydrate

    3-Oxobutanoyl-coenzyme A sodium hydrate

    		 Endogenous Metabolite Metabolic Disease
    Acetoacetyl CoA sodium hydrate is the precursor of HMG-CoA in the mevalonate pathway. Acetoacetyl-CoA thiolase catalyzes the reaction to form acetoacetyl-CoA sodium hydrate from two acetyl-CoA molecules. Acetoacetyl CoA sodium hydrate is essential for cholesterol biosynthesis. Acetoacetyl-CoA sodium hydrate is also a intermediate in the biological breakdown and synthesis of fatty acids .
    Acetoacetyl-CoA sodium hydrate
  • HY-16274
    Lapaquistat acetate

    TAK-475

    		 Farnesyl Transferase Metabolic Disease
    Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene in the cholesterol biosynthesis pathway . Lapaquistat acetate is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage. Lapaquistat acetate is used for hypercholesterolemia and mevalonate kinase deficiency (MKD) research .
    Lapaquistat acetate
  • HY-W415921
    1-Deoxy-D-threo-pentulose

    		Biochemical Assay Reagents
    1-Deoxy-D-threo-pentulose is a derivative of D-xylulose, which has application activity in the study of mevalonate pathway. 1-Deoxy-D-threo-pentulose is widely used to explore the mechanism of cell metabolism. 1-Deoxy-D-threo-pentulose has important experimental value in biochemical research.
    1-Deoxy-D-threo-pentulose
  • HY-107855
    DL-Mevalonolactone
    1 Publications Verification

    (±)-Mevalonolactone; Mevalolactone

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling [2][4].
    DL-Mevalonolactone
  • HY-N9923
    2-C-Methyl-D-erythritol 4-phosphate

    		Bacterial
    2-C-Methyl-D-erythritol 4-phosphate is a metabolite intermediate exclusive to the non-mevalonate MEP pathway, predominantly found in prokaryotes, serving as a precursor for the synthesis of isoprenoids and non-isoprenoids, including vitamins; its absence in humans makes it a promising target for the development of bacterium-specific drugs aimed at treating infectious diseases.
    2-C-Methyl-D-erythritol 4-phosphate
  • HY-107855S
    DL-Mevalonolactone-d7

    (±)-Mevalonolactone-d7; Mevalolactone-d7

    		 Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone-d7 is the deuterium labeled DL-Mevalonolactone. DL-Mevalonolactone ((±)-Mevalonolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential (?Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .
    DL-Mevalonolactone-d7
  • HY-107855S1
    DL-Mevalonolactone-d3

    (±)-Mevalonolactone-d3; Mevalolactone-d3

    		 Endogenous Metabolite Metabolic Disease
    DL-Mevalonolactone-d3 is the deuterium labeled DL-Mevalonolactone . DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone (Mevalonolactone) decreases mitochondrial membrane potential ( Ψm), NAD(P)H content and the capacity to retain Ca2+ in the brain, besides inducing mitochondrial swelling .
    DL-Mevalonolactone-d3
  • HY-113037B
    Farnesyl pyrophosphate

    Farnesyl diphosphate

    		 TRP Channel Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate
  • HY-151965
    Antimalarial agent 18

    		Parasite Infection
    Antimalarial agent 18 is an potent antimalarial agent, based on electronic, highly lipophilic and siderophoric properties. Antimalarial agent 18 belongs to acyloxymethyl series, as a fosmidomycin surrogate, which is potent IspC inhibitor against the non-mevalonate isoprenoid biosynthesis pathway. Antimalarial agent 18 inhibits P. falciparum (IC50=50 nM) and A. baumanii (IC50=390 nM) .
    Antimalarial agent 18
  • HY-18714
    BRD7116

    		Others Cancer
    BRD7116 is a cell-non-autonomous inhibitor of leukemic stem cells (LSCs). BRD7116, without directly contacting LSCs, can inhibit LSCs merely by altering the microenvironment. BRD7116 also has any cell-autonomous effects on LSCs and induces transcriptional changes consistent with myeloid differentiation. BRD7116 can be used for the study of leukemia .
    BRD7116
  • HY-134891
    HMBPP lithium

    (E)-4-Hydroxy-3-methyl-but-2-enyl diphosphate lithium

    		 Nuclear Factor of activated T Cells (NFAT) Infection Inflammation/Immunology
    HMBPP lithium is an intermediate in isoprenoid biosynthesis that can be produced by bacteria and protozoa that use the non-mevalonate pathway for isoprenoid biosynthesis. HMBPP lithium is a ligand of the internal domain of BTN3A1 and is an activator for human Vγ9/Vδ2 T cells. HMBPP lithium exhibits phagostimulant property in mosquitos .
    HMBPP lithium
  • HY-107855R
    DL-Mevalonolactone (Standard)

    		Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    DL-Mevalonolactone (Standard) is the analytical standard of DL-Mevalonolactone. This product is intended for research and analytical applications. DL-Mevalonolactone ((±)-Mevalonolactone;Mevalolactone) is the δ-lactone form of mevalonic acid, a precursor in the mevalonate pathway. DL-Mevalonolactone is orally active against HMGCR mutation and statin caused myopathy . DL-Mevalonolactone induces inflammation and oxidative stress response with decreased mitochondrial membrane potential (MMP) and induces mitochondrial swelling .
    DL-Mevalonolactone (Standard)
  • HY-113037C
    Farnesyl pyrophosphate ammonium

    Farnesyl diphosphate ammonium

    		 TRP Channel Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate (Farnesyl diphosphate) ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases .
    Farnesyl pyrophosphate ammonium
  • HY-19671
    Apomine

    SR-45023A; SR 9223i; SK&F-99085

    		 HMG-CoA Reductase (HMGCR) Apoptosis Cancer
    Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .
    Apomine
  • HY-113037S1
    Farnesyl pyrophosphate-d3

    Farnesyl diphosphate-d3

    		 TRP Channel Isotope-Labeled Compounds Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate-d3 (Farnesyl diphosphate-d3) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d3
  • HY-113037AS
    Farnesyl pyrophosphate-d6

    Farnesyl diphosphate-d6

    		 Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate-d6 (Farnesyl diphosphate-d6) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d6
  • HY-B0515B
    Ibandronate Sodium

    		Apoptosis Metabolic Disease Cancer
    Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium
  • HY-113037CS
    Farnesyl pyrophosphate-d2 triammonium

    Farnesyl diphosphate-d2 triammonium

    		 Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel Neurological Disease Inflammation/Immunology Cancer
    Farnesyl pyrophosphate-d2 (Farnesyl diphosphate-d2) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.
    Farnesyl pyrophosphate-d2 triammonium
  • HY-B0515
    Ibandronate Sodium Monohydrate
    1 Publications Verification

    BM-210955; RPR-102289A

    		 Apoptosis Metabolic Disease Cancer
    Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium Monohydrate
  • HY-B0515R
    Ibandronate Sodium Monohydrate (Standard)

    BM-210955 (Standard); RPR-102289A (Standard)

    		 Reference Standards Apoptosis Cancer
    Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) (Standard) is the analytical standard of Ibandronate Sodium Monohydrate (HY-B0515). This product is intended for research and analytical applications. Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium Monohydrate (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: